Gilead again backs AlloVir's T cell therapy in $127M direct offering

Kyle LaHucik

Senior Reporter

Gilead and a host of other companies are once again backing T cell immunotherapy biotech AlloVir in a direct offering that will provide the drugmaker …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Gilead again backs AlloVir's T cell therapy in $127M direct offering

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

BeiGene will rebrand to BeOne Medicines, dropping name's link to China roots

Merck buys into PD-1/VEGF space as Summit comes for Keytruda

As bluebird projects more commercial demand, the biotech continues to seek cash

Zai Lab aims to raise $200M; Kronos Bio to seek ‘strategic’ options

Exclusive: Ascidian CEO Michael Ehlers leaves Apple Tree Partners for MPM BioImpact

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?

Gilead again backs AlloVir's T cell ther­a­py in $127M di­rect of­fer­ing

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

As blue­bird projects more com­mer­cial de­mand, the biotech con­tin­ues to seek cash

Zai Lab aims to raise $200M; Kro­nos Bio to seek ‘strate­gic’ op­tions

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

Gilead again backs AlloVir's T cell therapy in $127M direct offering

BeiGene will rebrand to BeOne Medicines, dropping name's link to China roots

Merck buys into PD-1/VEGF space as Summit comes for Keytruda

As bluebird projects more commercial demand, the biotech continues to seek cash

Zai Lab aims to raise $200M; Kronos Bio to seek ‘strategic’ options

Exclusive: Ascidian CEO Michael Ehlers leaves Apple Tree Partners for MPM BioImpact

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?